

Poster presentation

Open Access

Contrast-enhanced whole heart coronary MRI with a bolus infusion of gadobenate dimeglumine at 1.5 T

Peng Hu^{*1}, Jonathan Chan¹, Jouke Smink², Beth Goddu¹, Kraig V Kissinger¹, Lois Goepfert¹, Warren J Manning¹ and Reza Nezafat¹

Address: ¹Beth Israel Deaconess Medical Center, Boston, MA, USA and ²Philips Healthcare, Best, Netherlands

* Corresponding author

from 13th Annual SCMR Scientific Sessions
Phoenix, AZ, USA. 21-24 January 2010

Published: 21 January 2010

Journal of Cardiovascular Magnetic Resonance 2010, 12(Suppl 1):P51 doi:10.1186/1532-429X-12-S1-P51

This abstract is available from: <http://jcmr-online.com/content/12/S1/P51>

© 2010 Hu et al; licensee BioMed Central Ltd.

Introduction

The potential benefits of contrast agents have been studied for coronary MRI; however the contrast timing/injection rate and sequence remain to be optimized. We investigated three infusion schemes (bolus, hybrid, slow) of gadobenate dimeglumine ([Gd-BOPTA]²⁺; MultiHance; Bracco Imaging SpA, Milan, Italy), a high relaxivity extracellular contrast agent, for improved whole-heart coronary MRI by measuring blood T₁ kinetics. Subsequently, we developed a contrast-enhanced whole-heart coronary MRI method at 1.5 T using an inversion-recovery SSFP sequence acquired after a bolus infusion.

Methods

Four healthy adult subjects were imaged three times each using three infusion schemes: a) bolus (0.2 mmol/kg @ 2 ml/s), b) hybrid (0.1 mmol/kg @ 2 ml/s plus 0.1 mmol/kg @ 0.1 ml/s), and c) slow (0.2 mmol/kg @ 0.3 ml/s). A Look-Locker sequence was used for quantitative T₁ measurements. Subsequently, seven healthy subjects were recruited for evaluation of a contrast-enhanced whole-heart coronary MRI with a bolus infusion. Free-breathing SSFP coronary MRI (TR/TE/α = 3.6/1.8/90°, FOV = 300 × 300 × 120 mm³, resolution = 1.3 × 1.3 × 1.3 mm³, T₂-Prep, ×2 accelerated) was performed before contrast injection. Gd-BOPTA (0.2 mmol/kg @ 2 ml/s) was injected intravenously, immediately followed by a Look-Locker sequence to visually determine the optimal inversion time. A contrast-enhanced whole-heart coronary was then acquired with identical imaging parameters with the exception of replac-

ing the T₂-Prep with a non-selective inversion pulse. For both acquisitions, a noise scan was performed immediately after acquisition. The blood SNR and blood-myocardium CNR were measured.

Results

Figure 1 shows the blood T₁ during the first 10 min after contrast injection. The bolus injection yields the fastest




Figure 1
Time course of blood T₁ up to 10 minutes after contrast injection using three infusion schemes.




Figure 2
Example coronary images acquired on a healthy subject using an SSFP sequence before (top row) and after (bottom row) a bolus injection of Gd-BOPTA.

and largest T_1 reduction in the initial 1-2 minutes. Slow infusion reduces the T_1 at a slower pace than bolus, but was similar to bolus ~ 2-3 min after injection. A hybrid infusion results in the lowest decrease in T_1 , but also the most stable. Figure 2 shows a comparison of contrast-enhanced and non-contrast coronary images. The coronary SNR and CNR were significantly improved by 36% (58.5 ± 18.7 vs. 79.5 ± 17.5) and 101% (27.3 ± 11.4 vs.

55.0 ± 12.1), respectively ($p < 0.003$ for both). Figure 3 shows reformatted examples of the LAD, which shows improved visualization of mid and distal LAD.

Conclusion

Contrast-enhanced whole heart coronary MRI with a bolus infusion of Gd-BOPTA using inversion-recovery SSFP at 1.5 T results in enhanced SNR and CNR.




Figure 3
Reformatted non-contrast (a) and contrast-enhanced (b) LAD images. The improved suppression of myocardial signal using Gd-BOPTA facilitates depiction of mid and distal coronary artery.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

